Induction chemotherapy in locoregionally advanced nasopharyngeal carcinoma: A systematic review and meta-analysis

Wang, Bi-Cheng; Kuang, Bo-Hua; Liu, Xin-Xiu; Lin, Guo-He; Liu, Quentin

doi:10.3389/fonc.2022.927510

Cited by 2 publications

(1 citation statement)

References 64 publications

(21 reference statements)

Supporting

Mentioning

Contrasting

Order By: Relevance

“…4,7,8 Recently, a higher incidence of nausea and vomiting has been reported in patients with head and neck squamous cell carcinomas (HNSCC) treated with IMRT due to a higher dose deposited on the brainstem, considering the conformity, [9][10][11][12][13][14] and nausea and vomiting in NPC during IMRT may be underestimated. 4,15 Therefore, a need exists for an intensified antiemetic prophylaxis to improve control of nausea and emesis during combined radiotherapy-HEC.…”

Section: Introductionmentioning

confidence: 99%

Fosaprepitant Weekly vs Every 3 Weeks for the Prevention of Concurrent Chemoradiotherapy–Induced Nausea and Vomiting

et al. 2023

View full text Add to dashboard Cite

ImportanceUnlike substantial evidence in the prevention of chemotherapy-induced nausea and vomiting (CINV), research in the prevention of nausea and vomiting caused by concurrent chemoradiotherapy (CCRT) is currently lacking.ObjectiveTo compare the efficacy and safety of fosaprepitant weekly vs every 3 weeks for the prevention of nausea and emesis caused by CCRT among patients with nasopharyngeal carcinoma.Design, Setting, and ParticipantsThis pilot randomized clinical trial was conducted at a single cancer center from November 24, 2020, to July 26, 2021, among patients with nasopharyngeal carcinoma who had achieved CINV control after 2 to 3 cycles of induction chemotherapy. Efficacy analyses were performed in the intention-to-treat population. Data were analyzed on November 4, 2022.InterventionsEligible patients were randomly assigned (1:1) to receive fosaprepitant either weekly or every 3 weeks.Main Outcomes and MeasuresThe primary end point was the proportion of patients with sustained complete response (defined as no emesis and no rescue therapy) during CCRT. Secondary end points were sustained no emesis, no nausea, no significant nausea, mean time to first emetic episode, quality of life, and 1-year progression-free survival (PFS).ResultsA total of 100 patients (mean [SD] age, 46.6 [10.9] years; 83 [83.0%] male) who had achieved CINV control after induction chemotherapy were randomly assigned to receive fosaprepitant weekly (50 patients) or every 3 weeks (50 patients). There was no significantly significant difference in cumulative risk of emesis or rescue therapy in the group that received weekly fosaprepitant compared with those who received fosaprepitant every 3 weeks (subhazard ratio, 0.66 [95% CI, 0.43-1.02]; P = .06). The proportion of patients with sustained no emesis (38% vs 14%; P = .003) or no significant nausea (92% vs 72%; P = .002) was significantly higher in the group that received fosaprepitant weekly vs those who received fosaprepitant every 3 weeks. Treatments were well tolerated. Patients in the weekly group had improved scores for multiple quality-of-life measures. There was no significant difference in survival outcomes between groups (91.8% vs 93.7%; P = .99). In the mean brainstem dose subgroups, a possible treatment interaction effect was observed in sustained complete response (mean brainstem dose ≥36 Gy: hazard ratio [HR], 0.32 [95% CI, 0.15-0.69]; mean brainstem dose &lt;36 Gy: HR, 0.95 [95% CI, 0.55-1.63]) and sustained no emesis (mean brainstem dose ≥36 Gy: HR, 0.21 [95% CI, 0.08-0.53]; mean brainstem dose &lt;36 Gy: HR, 0.73 [95% CI, 0.41-1.28]).Conclusions and RelevanceIn this pilot randomized clinical trial, there was no statistically significant difference in the complete response primary end point, but patients receiving weekly fosaprepitant were less likely to experience emesis compared with those who received fosaprepitant every 3 weeks, especially in the subgroup with a mean brainstem dose of 36 Gy or more. Weekly fosaprepitant was well tolerated and improved quality of life of patients without compromising survival.Trial RegistrationClinicalTrials.gov Identifier: NCT04636632

show abstract